VanEck Vectors Israel ETF Newsroom

Teva Pharmaceutical Indus Analyst Ratings

BenzingaJun 27 23:38

Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23

BenzingaJun 27 23:38

CyberArk Software Analyst Ratings

BenzingaJun 26 00:25

Guggenheim Reiterates Buy on CyberArk Software, Maintains $300 Price Target

BenzingaJun 26 00:25

CyberArk Software Analyst Ratings

BenzingaJun 22 00:55

Cantor Fitzgerald Reiterates Overweight on CyberArk Software, Maintains $300 Price Target

BenzingaJun 22 00:55

JMP Securities Reiterates Market Outperform on CyberArk Software, Maintains $310 Price Target

BenzingaJun 17 20:16

CyberArk Software Analyst Ratings

BenzingaJun 17 20:14

Morgan Stanley Maintains Overweight on NICE, Lowers Price Target to $240

BenzingaJun 14 21:02

Northland Capital Markets Maintains Outperform on NICE, Maintains $305 Price Target

BenzingaJun 14 01:22

Citigroup Maintains Buy on NICE, Raises Price Target to $346

BenzingaJun 13 02:36

Wedbush Reiterates Outperform on NICE, Maintains $250 Price Target

BenzingaJun 12 22:54

NICE Analyst Ratings

BenzingaJun 12 19:05

Rosenblatt Maintains Buy on NICE, Lowers Price Target to $225

BenzingaJun 12 19:05

RBC Capital Cuts Price Target on NICE to $230 From $265, Maintains Outperform Rating

MT NewswiresJun 12 18:25

Wix.com Analyst Ratings

BenzingaJun 6 20:50

B of A Securities Maintains Buy on Wix.com, Raises Price Target to $183

BenzingaJun 6 20:50

Teva Pharmaceutical Indus Analyst Ratings

BenzingaJun 5 23:20

CyberArk Software Analyst Ratings

BenzingaJun 4 21:55

Canaccord Genuity Maintains Buy on CyberArk Software, Lowers Price Target to $280

BenzingaJun 4 21:55